logo-loader
viewEsperion Therapeutics Inc

Esperion Therapeutics wins FDA approval on a pair of new drug applications; shares jump

Bempedoic acid and the bempedoic acid ezetimibe combination tablet are designed to decreased lipid levels in patients with elevated low-density lipoprotein cholesterol

keyboard that says 'FDA approved' on the shift key, as well as a literal key
The next step is filing and regulatory review, which the FDA hopes to complete in February 2020

Esperion Therapeutics Inc (NASDAQ:ESPR) said it has earned the Food and Drug Administration's approval on two new drug applications, sending the shares higher Monday.

Bempedoic acid and the bempedoic acid ezetimibe combination tablet are designed to decreased lipid levels in patients with elevated low-density lipoprotein cholesterol. The next step is filing and regulatory review.

The stock jumped more than 12% to $48.47.

READ: Esperion Therapeutics shares pop on successful Phase 3 trial for bempedoic acid

“It is exceptional that our New Drug Applications for both bempedoic acid and bempedoic acid ezetimibe combination tablet have been accepted for filing,” President and CEO Tim Mayleben said. “The acceptances validate the extraordinary effort and high-quality submissions of our lipid management team and brings our once-daily, oral bempedoic acid-based therapies one step closer to the physicians and patients who will benefit from them.”

The FDA’s goal dates for completing the regulatory review are in February 2020. There is no plan to hold an advisory committee meeting currently in place.

Esperion, also known as the the lipid management company, is focused on developing once-daily oral therapies for patients with high LDL-Cholesterol.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Esperion Therapeutics Inc

Price: 43.51 USD

NASDAQ:ESPR
Market: NASDAQ
Market Cap: $1.2 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: InnoCan Pharma signs deal with ADVA Biotechnology to produce...

InnoCann Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has signed a Letter of Intent with ADVA Bio-Technology for exosome manufacturing and development. Bincovich telling Proactive InnoCan intends to load the produced exosomes with...

42 minutes ago

2 min read